BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: Precision oncology has been expanding beyond BRCA1/2 testing and the evaluation of homologous recombination deficiency (HRD) as a biomarker associated with PARP inhibitors response represents an important clinical issue [53,54,55].